Register entry
Biofrontera Bioscience GmbH
- Registered sites
- 1
- Drug products
- 1
- Live patents
- 3
- Countries
- 1
- Base
- Germany
Authorisation
Registered operations
What the FDA has registered these sites to do. This is the regulatory record, not a marketing claim.
Analytical testing
Sites
Facilities
1| Site | Location | Operations | FEI |
|---|---|---|---|
| Biofrontera Pharma GmbH | LeverkusenGermany | Analytical testing | 3011764519 |
Exclusivity
Patents
3Unexpired Orange Book patents where this company is the application holder.
| Product | Active ingredient | Expiry |
|---|---|---|
| AMELUZ | AMINOLEVULINIC ACID HYDROCHLORIDE | Feb 2028 |
| AMELUZ | AMINOLEVULINIC ACID HYDROCHLORIDE | Oct 2040 |
| AMELUZ | AMINOLEVULINIC ACID HYDROCHLORIDE | Dec 2043 |
Catalogue
Marketed products
1Showing 1 of 1.
| Brand | Generic name | Form | Category |
|---|---|---|---|
| AMELUZ | aminolevulinic acid hydrochloride | GEL | NDA |
Provenance
Facility and operations data from the FDA Drug Establishments Current Registration Site. Product data from the openFDA National Drug Code Directory. Patent and exclusivity data from the FDA Orange Book. Shortage data from the FDA drug shortage database. Contact details the FDA publishes for registered establishments are deliberately not reproduced here. This entry is compiled from public records and has not been claimed by the company.